Immune checkpoint inhibitors (ICI) blocking CTLA-4 (e.g., ipilimumab), PD-1 (e.g., nivolumab, pembrolizumab), or PD-L1 (e.g., atezolizumab, avelumab, durvalumab) have demonstrated objective tumor regressions in patients with advanced melanoma and other cancer types. Some drugs and drug combinations (e.g., nivolumab plus ipilimumab) can prolong survival in patients with melanoma (1, 2) . However, these drugs have mechanisms of action which differ from targeted agents and traditional cytotoxic chemotherapies, making assessment of therapeutic benefit (or lack thereof) in a given patient challenging, especially soon after initiation of therapy. In some cases, tumors assessed using standard computed tomographic (CT) imaging appear to enlarge before later regressing, likely due to the infiltration and proliferation of lymphocytes and other immune cells. Other tumors remain stable in size for a prolonged period of time, even after therapy has been stopped (3-6). Indeed, a variety of radiologic responses to ICI have been described, some of which are linked to therapeutic benefit (7, 8) (12) (13) (14) Results from these studies and others suggest that functional imaging information obtained from FDG-PET/CT scans may complement data from anatomic imaging studies such as conventional spiral CT scanning and magnetic resonance imaging (MRI).
Two FDG-PET-based tumor response evaluation criteria commonly used in studies of patients with solid tumors are 1) PET Response Criteria in Solid Tumors (PERCIST 1.0), and 2) European Organisation for Research and Treatment of Cancer (EORTC) 1999 criteria (15, 16) . Using these metrics, disease response to therapy has been evaluated in multiple studies encompassing a variety of tumor types (17) (18) (19) .
In order to investigate the utility of FDG-PET/CT as a tool to detect early evidence of response in patients with advanced melanoma receiving immune checkpoint blocking agents, we prospectively performed serial FDG-PET/CT imaging in patients with advanced melanoma undergoing ICI therapy, conducted several analyses in order to characterize changes in tumor burden and functional parameters, and utilized these data to develop criteria to predict eventual clinical response to therapy.
MATERIALS AND METHODS

Study Design
This study was approved by the Johns Hopkins University and University of Wisconsin-Madison Institutional Review Boards (IRB) in accordance with an assurance filed with and approved by the Department of Health and Human Services Subjects (ClinicalTrials.gov number NCT01666353). As per IRB requirements, study data was anonymized during data collection and analysis. Twenty adult patients who were scheduled to initiate ICI therapy as their first or later systemic treatment for metastatic or unresectable melanoma at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center provided written informed consent to participate in this prospective study between by NYU Med Ctr Lib -Periodicals Dept on March 31, 2017. For personal use only. jnm.snmjournals.org Downloaded from April 2012 and December 2013. Subjects were required to have at least one lesion, >10mm, that could be accurately measured in at least one dimension with spiral CT scan. Patients were treated with ipilimumab at 3mg/kg intravenously every 3 weeks for a maximum of 4 doses (anti-CTLA-4; n=16); BMS-936559 at 0.1-1 mg/kg intravenously every 2 weeks until complete response, disease progression or dose-limiting toxicity (anti-PD-L1; n=3; ClinicalTrials.gov number, NCT00729664, Ref. (20)); or nivolumab 3 mg/kg every 2 weeks (anti-PD-1; n=1; ClinicalTrials.gov number NCT01621490; Ref. (21)). FDG-PET/CT imaging was performed within four weeks prior to initiating therapy (SCAN-1), again between days 21 and 28 on therapy (SCAN-2), and at approximately 4 months after treatment initiation (SCAN-3). Patients were observed until death or initiation of subsequent therapy for disease progression. Of note, because of the investigational nature of SCAN-2, data from that scan were not used to guide patient management decisions.
Evaluable patients were required to have received at least two doses of ICI therapy and have undergone SCAN-1, SCAN-2, and at least one additional evaluation (radiographic or clinical) thereafter. Due to the poor performance of PET/CT imaging to detect brain metastases, intracranial lesions were not included in disease assessments.
Imaging
FDG-PET/CT images were acquired on a Discovery DRX PET/CT scanner (GE Healthcare). FDG-PET/CT scan was performed according to the Uniform Protocols for 
Response Evaluation
FDG-PET/CT images were reviewed and analyzed using MIRADA XD3 software (MIRADA Medical, Denver, CO, USA) by two nuclear medicine specialists with convened consensus review of PET and CT response evaluation. CT-based responses, assessed by study investigators, were characterized according to RECIST1.1 (23) and irRC (9). FDG-PET-based responses were evaluated using PERCIST 1.0 (24,25), and EORTC 1999 criteria (16) . Response criteria used in this study are summarized in Table 1 . Because EORTC 1999 criteria do not include a pre-specified number of target lesions, we considered all FDG-avid lesions at SCAN-1 as target lesions. An FDG-avid lesion was defined as focal, abnormally increased FDG uptake versus background with a corresponding anatomic lesion seen on CT scan, suggestive of metastasis.
CT-based anti-tumor responses based on changes observed from SCAN-1 to SCAN-2 and SCAN-1 to SCAN-3 were classified as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD). FDG-PET-based responses were classified as complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD) or progressive metabolic disease (PMD).
Percentage change in lesion dimensions (CT) or FDG-avidity (PET) from SCAN-1 to SCAN-2 were calculated using the following formula: [(SCAN-2 -SCAN-1)/SCAN-1)*100].
The same formula was adapted for SCAN-1 to SCAN-3 calculations subtracting the SCAN 1 result from the SCAN 3 result. During and after the study period, patients were followed per standard-of-care imaging and clinical follow-up in order to assess best overall response (BOR) to ICI therapy. The duration of observation for each patient is included in Table 2 . Radiographic changes observed at SCAN-2 were analyzed for their capacity to predict eventual clinical benefit, which we defined as CR or PR at 4 months or SD lasting at least 6 months. Confirmatory scans for PR and CR seen at SCAN-3 were not required.
Outcomes Analysis
Inter-criteria agreements at SCAN-2 and SCAN-3 were assessed using kappa coefficients (26). The positive and negative predictive values of outcomes at SCAN-2 for clinical benefit were assessed for all four criteria. Receiver operating characteristic (ROC) analysis was used to assess the predictive value of continuous measurements and to find the optimal cutoff of measurements to predict clinical benefit. Pearson's correlation coefficient (r) was used for correlation analysis. Finally, a combined functional/anatomical approach was developed and evaluated to enhance the predictive value of the FDG-PET and CT measurements at SCAN-2 for clinical benefit. Statistical analyses were performed using MedCalc software version 10.1 (MedCalc Software, Belgium).
RESULTS
Patient Characteristics
Twenty subjects were enrolled on the trial. Their mean age was 59.2 years (range, 42-72) . Seven were female. Eleven patients had previously received systemic therapy for advanced melanoma, including nilotinib, high-dose interleukin-2, temozolomide. One patient who received ipilimumab on the present trial had previously received nivolumab. All 20 enrolled subjects with metastatic melanoma were evaluable for response to therapy with immune checkpoint inhibitors. Sixteen patients received ipilimumab (anti-CTLA-4) as a standard-of-care therapy in the first or later line setting. Three patients received BMS-936559 (anti-PD-L1) on a clinical trial in the second line setting. One patient received nivolumab (anti-PD-1) on a clinical trial in the first-line setting.
Treatment Response
Tumor responses were measured by PET-CT according to four different criteria systems, after 3-4 weeks of treatment (SCAN-2) and at about 4 months (SCAN-3) ( Table   2 ). The best overall responses for each patient, including information from standard-ofcare radiographic imaging performed in addition to SCAN-2 and SCAN-3, are included in Table 2 .
Five subjects classified as having derived clinical benefit from ICI therapy included 2 patients with CR at 4 months, 2 patients with PR at 4 months, and 1 patient with SD lasting 9 months. The five subjects had been treated with ipilimumab. The remaining 15 patients experienced stable disease lasting less than 6 months, or PD. No patient with an early assessment categorized as PD by RECIST1.1 later experienced an objective response to therapy.
Of note, baseline scans for patient 11 demonstrated a 1.1cm retroperitoneal lymph node, proven by fine needle aspirate to be metastatic melanoma. Although the patient met study entry criteria (at least one lesion, >10mm, that could be accurately measured in at least one dimension with spiral CT scan), the tumor did not qualify as "measurable" by RECIST 1.1 criteria (≥1.5 cm short diameter). However, because the lesion was proven to be tumor by biopsy, and because we were able to measure it at baseline and after administration of therapy, we included this patient in our study.
Comparisons of Response Evaluations at SCAN-2 and SCAN-3
Comparisons of tumor response measurement criteria at SCAN-2, performed 21-28 Table 1 ).
Findings on Early PET/CT Associated with Eventual Clinical Outcomes
At SCAN-2, of the four metrics assessed, RECIST 1.1 demonstrated the highest predictive value for BOR at ≥4 months (Accuracy=75% ; Table 3 ). ROC analysis revealed that percent change from SCAN-1 to SCAN-2 using RECIST1.1, irRC, PERCIST and EORTC criteria were predictive for BOR at ≥4 months as follows: area under curve = 0.853, 0.827, 0.680, and 0.600, respectively (Supplemental Table 2 ).
Based on the percent change from SCAN-1 to SCAN-2 of target lesion dimensions (CT) or FDG uptake (PET), we derived the predictive values of these measurements based on optimal threshold values, calculated using ROC analysis, to forecast outcomes at 4 months ( Table 4) . Percent change per RECIST1.1 had the highest predictive value with an accuracy of 85%. Intriguingly, optimal PERCIST and EORTC threshold values predictive of BOR were >15.5% and >14.7%, respectively, indicating that increased FDG tumor uptake at SCAN-2 may correlate with eventual clinical benefit. Incorporating optimal thresholds using RECIST-based and PERCIST-based changes at SCAN-2, visualized on a 2-dimensional plot (Fig. 1) , we retrospectively developed criteria for early of prediction eventual response (PET/CT criteria for Early Prediction of Response to ICI Therapy, PEPRIT) (Fig. 2) . Patients whose CT scans demonstrated an objective response by RECIST 1.1 at SCAN-2 maintained a response at 4 months. Similarly, progressive disease by RECIST 1.1 at SCAN-2 was associated with disease progression at 4 months. However, in patients with stable disease at SCAN-2, an increase >15.5% in SULpeak of the hottest lesion was associated with eventual clinical benefit, providing a potentially informative indicator based on dual criteria. A case study is provided in Fig. 3 . The sensitivity, specificity and accuracy of the proposed criteria to predict response by RECIST1.1 at 4 months were 100%, 93.3% and 95.0 %, respectively ( Table 4) . The predictive capacities of four different methods of measurement of changes in tumor burden from SCAN-1 to SCAN-2 to predict eventual response are provided in Supplemental Table 3 .
DISCUSSION
As the use of immune checkpoint blockade agents increases, so too does the challenge of assessing their anti-tumor efficacy in patients who's post-therapy CT scans may demonstrate unconventional or delayed patterns of response. Although a midtreatment tumor biopsy might provide useful information about the viability of tumor cells and the activity of the immune response within a lesion, biopsy is not always possible because tumors may be inaccessible and/or multiple. Additionally, biopsies of a single lesion may not accurately capture patients experiencing a mixed response (concomitant regression/progression of individual metastases). Thus, early, whole-body non-invasive indicators of drug efficacy could help to better predict which patients might respond to therapy and guide clinicians in adjusting treatment regimens as appropriate.
Even in patients where conventional CT scanning performed at traditional intervals (every 2-3 months) turns out to be an accurate gauge of therapeutic response, there may still be benefits to early identification of patients not predicted to respond. Early discontinuation of ICI could mitigate the risk for immune-related adverse events (irAEs), reduce the cost of the therapy, and allow for initiation of a different treatment approach.
Here, we prospectively evaluated the utility of a baseline and follow-up FDG-PET/CT scan, performed early in the course of ICI, as a predictor of BOR at ≥4 months.
Because human melanomas consistently have high glucose metabolism, FDG-PET/CT imaging is particularly well suited for detecting these tumors, some of which are difficult to identify by standard CT scans (27, 28) . PET imaging, performed as early as 7 days after initiation of radioimmunotherapy, has been shown to be predictive of outcomes in patients with lymphoma (29). However, glucose metabolism is sensitive but not specific for neoplastic growth, since other processes such as inflammation involve glucose utilization.
Indeed, FDG PET/CT has been used to detect and monitor treatment efficacy in various inflammatory/infectious processes such as osteomyelitis, prosthesis infection, fever of unknown origin, and sarcoidosis (30).
Consequently, we were not surprised to observe that patients with stable anatomic disease and modest to markedly increased FDG uptake at SCAN-2 tended to demonstrate eventual tumor regression. Our findings suggest an early inflammatory response at the site Sachpekidis and colleagues performed a study similar to ours that investigated the predictive value of FDG-PET/CT performed after two cycles (approximately 6 weeks) of ipilimumab in predicting final response to therapy (33). Response classifications were based on EORTC 1999 criteria, which mainly incorporates changes in tumor metabolic activity rather than changes in tumor dimensions. The two patients on that study who demonstrated a partial metabolic response at the end of treatment were metabolically classified as having progressive metabolic disease on early PET/CT. Thus, the authors concluded that those two patients were incorrectly classified based on early PET/CT. The results of our study suggest that a combination of changes in lesional dimensions along with changes in FDG uptake may provide a more accurate predictor of eventual response.
Inter-criteria agreements between RECIST 1.1, PERCIST, and EORTC were good to excellent at SCAN-3, performed 4 months after initiating ICI, which is in accordance with a previous report using cytotoxic chemotherapy (19). However, interestingly, inter-criteria agreement between the PET and CT modalities was not good in the early course of ICI therapy. This disagreement should be caused by the paradoxically increased FDG uptake in the responding tumor in the early course of ICI therapy. Thus we could incorporate the different response information from PET and CT to propose a early response criteria, PERPRIT.
Other potential methods for prediction of ICI therapy response include measurement of circulating tumor DNA (ctDNA) in plasma. Small trials have shown that ctDNA level changes can mirror radiological changes in tumor burden, and may predict eventual response to ICI (34,35). These emerging technologies, which require only serial blood sampling and laboratory analysis, may compare favorably to PET/CT in terms of feasibility and accessibility among an increasing population of patients undergoing therapy with ICI.
Our study is limited by a relatively small sample size, a lack of intravenous contrast agent in many of the CT scans and a predominance of anti-CTLA-4 directed therapy.
Additionally, brain MRIs were not routinely performed as a part of our investigation, and because PET/CT imaging is not well-suited for detecting melanoma brain metastases, patients may have had undetected brain metastases during the study period. However, these preliminary findings suggest that PET/CT scans performed early in the course of ICI therapy, particularly ipilimumab, appear predictive for eventual response in patients with 
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